1 / 17

Promoting Patient Involvement in Medication Decisions

Goals of this Session. Review concepts of shared decision making.Describe results of fous groups to assess consumers' perceptions of sources of medical information.Describe our work developing tools to promote shared decision making.. The Role of Evidence in Shared Decision Making. What is eviden

isra
Download Presentation

Promoting Patient Involvement in Medication Decisions

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


    1. Promoting Patient Involvement in Medication Decisions David H. Hickam, MD, MPH Professor, Dept. of Medicine Oregon Health & Science University Portland, Oregon

    2. Goals of this Session Review concepts of shared decision making. Describe results of fous groups to assess consumers’ perceptions of sources of medical information. Describe our work developing tools to promote shared decision making.

    3. The Role of Evidence in Shared Decision Making What is evidence? How does evidence inform medical decisions? Can clinicians and patients communicate about evidence? Are simple evidence-based decision tools useful?

    4. Clinical Problems for which Decision Aids are Useful

    5. Options for Tools to Promote Shared Decision Making simple: (provide probabilities, summary preferences in literature or by other patients or list of advantages disadvantages, coached steps toward decision). Or complex: all of above plus one or more of the following: customized risk tools, probabilities that adjust with risk level, explicit values clarification, etc. simple: (provide probabilities, summary preferences in literature or by other patients or list of advantages disadvantages, coached steps toward decision). Or complex: all of above plus one or more of the following: customized risk tools, probabilities that adjust with risk level, explicit values clarification, etc. simple: (provide probabilities, summary preferences in literature or by other patients or list of advantages disadvantages, coached steps toward decision).

    6. Focus Groups to Assess Consumers’ Perceptions of Information Sources Perceived need for information about conditions and treatments. Perceptions about sharing decisions with clinicians. Where the participants obtain information. Brief review of examples.

    7. Focus Group Participants 18 focus groups (total of 113 participants) Membership in each group defined by a particular chronic disease Arthritis Hypertension Type 2 diabetes Osteoporosis

    8. Focus Group Characteristics Two-thirds female 60% age 60 or greater 75% Caucasian 43% college graduates 44% had used Internet in last month. One-third rated their health as fair or poor.

    9. Preferences for Information Sources Short and easy to read. Many participants were not comfortable with Internet as information source. Desire for positive information: often an issue when evidence is “negative.” Framing of mortality information. Trusted sources of information such as government and, AARP, or the Arthritis Foundation Distrust in industry

    10. Preferences for Content of Information Sources Consensus that information about benefits is the most important. Participants understand benefit/harm trade-offs. Desire that side effect information be thorough. Comparison to “non-medical” treatments.

    11. Perspective about Interactions with Providers Consensus on value of shared decision making. Few participants reported collaborative, trusting relationships with clinicians. Clinic visits tend to be rushed. Some felt pressure to make hurried decisions. Skepticism about recommendations to “talk to your doctor.” Endorsement of tools that provide new information.

    12. Principles for the Use of Evidence in Decision Tools Include evidence about both benefits and harms of the alternatives. Indicate where the evidence in inconclusive. Make the information actionable. Need clarity about what the decisions are and how to approach those decisions.

    13. Key Features of Eisenberg Center Summary Guides Brief & focused on key messages Explicitly designed for audiences Style template Benefits, Risks, Trade-offs Plain language Appropriate literacy & numeracy levels Actionable information

    14. Up Front Bottom Line

    15. Understanding the Benefits

    16. Decision Coaching

    17. Actionable Numeric Data For treatments of early stage prostate cancer: Proportion of men reporting impotence following each treatment, at 2 years: 58% after radical prostatectomy 43% after radiation therapy 86% with hormonal therapy 33% with watchful waiting

    18. Conclusions about Evidence Translation Both clinicians and consumers are interested in evidence and believe that it influences decisions. Credibility is crucial. We do not know very much about how clinicians and patients communicate about evidence. Consumers perceive that evidence-based decision tools might be useful.

More Related